Klinische NET-Studien

Hier finden Sie Informationen zu den aktuellen klinischen Studien in diesem Bereich.

Sie befinden sich hier:

Ansprechpartner

Dr. med. Henning Jann

Funktionsoberarzt Neuroendokrine Tumore

Dr. Henning Jann, Hepatologie und Gastroenterologie, Funktionsoberarzt
Susanne Steglich

Studienschwester NET Prüfzentrale

Aktuelle klinische Studien NET(s)

CLARINET FORTE

Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days”as amended from time to time and incorporated herein by reference

Ansprechpartner: Dr. H. Jann

COMPETE

A prospective, randomised, Controled, Open-label, Multicentre phase lll study  to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSIR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)

Ansprechpartner: Dr. H. Jann

EVINEC 

Safety and tolerability of Everolimus as second-line treatment in poorly differenciated neuroendocrine carcinoma/neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3- an investigational initialled Phase II study/EVINEC

Ansprechpartner: Dr. H. Jann

NETTER-I

Eine multizentrische, stratifizierte, offene, randomisierte, vergleichsarmkontrollierte Parallelgruppenstudie der Phase-III zum Vergleich der Behandlung mit 177Lu-DOTA0-Tyr3-Octreotat mit langwirksamem Octreotid bei Patienten mit inoperablen, progressiven, somatostatinrezeptorpositiven Karzinoidtumoren des Mitteldarms.

Ansprechpartner: Dr. H. Jann

SEQTOR

Randomized open label study to compare the efficacy and safety of Everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by Everolimus upon progression, in advanced progressive pNETs

Ansprechpartner: Dr. H. Jann